2017 Volume 7 Issue 1 Pages 1-8
Allogeneic hematopoietic stem-cell transplantation is an effective therapeutic option for adults suffering from conditions such as acute myeloid leukemia, acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome. However, post-transplant relapse is still a challenge to be overcome. An intensified conditioning regimen with high-dose cytarabine (HDCA) added to cyclophosphamide/total-body irradiation (CY/TBI) has been developed to reduce post-transplant relapse. However, its additional effects have not yet been completely elucidated. Therefore, we conducted a cohort study to compare the prognosis of HDCA/CY/TBI and CY/TBI for myeloid malignancy and ALL. The superiority of HDCA/CY/TBI over CY/TBI was documented in cord blood transplantation, but not in bone marrow transplantation or peripheral blood stem cell transplantation. A large-scale prospective study is warranted for establishing the efficiency of the HDCA/CY/TBI conditioning regimen.
